NGM Biopharmaceuticals (NGM) Stock Analysis

NGM Biopharmaceuticals (NGM) Healthcare & Pipeline Overview

NGM Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm specializing in novel therapeutics for liver, metabolic, and retinal diseases, and cancer. Their pipeline features Aldafermin and MK-3655, both in Phase IIb trials targeting NASH and type 2 diabetes, positioning them in a competitive landscape focused on unmet medical needs.

What Is the Investment Thesis for NGM?

NGM Biopharmaceuticals presents a high-risk, high-reward investment profile typical of clinical-stage biotech companies. The primary value driver is the successful completion of Phase IIb trials for Aldafermin and MK-3655, targeting the large and growing NASH and type 2 diabetes markets. Positive data readouts could significantly increase the company's market capitalization, which currently stands at $0.13 billion. Key catalysts include upcoming clinical trial results and potential partnership agreements. However, the company's negative profit margin of -3223.3% underscores the need for successful commercialization or strategic partnerships to achieve profitability. The company's beta of 1.26 suggests higher volatility compared to the broader market. Investors should closely monitor clinical trial progress, regulatory developments, and cash burn rate.

Based on FMP financials and quantitative analysis

NGM Key Highlights

Market capitalization of $129M reflects the company's current valuation in the biotechnology sector.

• Gross margin of 49.7% indicates the potential for profitability upon successful commercialization of its product candidates.
• Negative profit margin of -3223.3% highlights the significant R&D expenses associated with clinical-stage drug development.
• Aldafermin and MK-3655 are in Phase IIb clinical trials, targeting the large NASH and type 2 diabetes markets.
• Collaboration agreements with Merck Sharp & Dohme Corp. and Merck & Co., Inc. provide financial support and validation of NGM's research programs.

Who Are NGM's Competitors?

NGM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NGM's Key Strengths?

Innovative drug discovery platform.

• Strong pipeline of clinical-stage drug candidates.
• Strategic collaborations with major pharmaceutical companies.
• Experienced management team.

What Are NGM's Weaknesses?

High cash burn rate due to significant R&D expenses.

• Reliance on successful clinical trial outcomes.
• Limited revenue generation prior to commercialization.
• Negative profit margin.

What Could Drive NGM Stock Higher?

NGM catalyst: Data readout from Phase IIb clinical trial of Aldafermin for NASH (expected in late 2026).

• Data readout from Phase IIb clinical trial of MK-3655 for type 2 diabetes and NASH (expected in early 2027).
• Progress in Phase I/II clinical trials for NGM120 and NGM707.
• Potential for new strategic partnerships and collaborations.
• Advancements in the development of NGM621 for geographic atrophy.

What Are the Key Risks for NGM?

Financial-distress signal — its Altman Z-Score of -4.08 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-69.8%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of Aldafermin or MK-3655 in Phase IIb or subsequent clinical trials.
• Regulatory delays or rejection of NGM's drug candidates.
• High cash burn rate and need for additional financing.
• Competition from other companies developing therapies for the same indications.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for NGM?

• Positive Phase IIb results for Aldafermin could position NGM as a key player in this space. The timeline for potential FDA approval and commercialization is estimated to be 3-5 years, contingent on successful Phase III trials. NGM's competitive advantage lies in Aldafermin's unique mechanism of action as an FGF19 analog.
• MK-3655 for Type 2 Diabetes and NASH: MK-3655 targets both type 2 diabetes and NASH, offering a dual-pronged approach to address these interconnected metabolic diseases. The global type 2 diabetes market is substantial, providing a significant commercial opportunity. Positive Phase IIb data could lead to partnerships or further development, with a similar 3-5 year timeline for potential commercialization. The competitive advantage lies in its agonistic antibody mechanism targeting fibroblast growth factor receptor 1c-beta-klotho.
• NGM621 for Geographic Atrophy: NGM621, currently in Phase II clinical trials, targets geographic atrophy, a significant cause of vision loss. The market for geographic atrophy treatments is growing, driven by an aging population. Successful trial outcomes could lead to a valuable asset in the retinal disease space, with potential commercialization within 4-6 years. Its competitive advantage is its immunoglobulin 1 monoclonal antibody mechanism.
• NGM707 for Advanced Solid Tumors: NGM707, a dual antagonist monoclonal antibody, is in Phase I/II trials for advanced solid tumors. The oncology market is vast, and successful development could lead to significant revenue streams. The timeline for potential commercialization is longer, estimated at 5-7 years, due to the early stage of development. Its competitive advantage lies in its dual-targeting mechanism of immunoglobulin-like transcript 2/immunoglobulin-like transcript 4.
• Strategic Partnerships: NGM's existing collaborations with Merck Sharp & Dohme Corp. and Merck & Co., Inc. provide a foundation for future partnerships. Expanding these collaborations or securing new partnerships could provide additional funding, expertise, and market access. The timeline for new partnerships is variable, but ongoing discussions and data readouts could catalyze new agreements within the next 1-2 years. These partnerships validate NGM's research and development capabilities.

What Opportunities Does NGM Have?

• Growing market for NASH and type 2 diabetes therapies.
• Potential for new strategic partnerships.
• Expansion of pipeline into new therapeutic areas.
• Positive clinical trial results leading to regulatory approvals.

What Threats Does NGM Face?

• Clinical trial failures.
• Regulatory setbacks.
• Competition from other pharmaceutical and biotechnology companies.
• Patent challenges.

What Are NGM's Competitive Advantages?

• Proprietary drug discovery platform generates novel therapeutic candidates.
• Strong intellectual property portfolio protects its drug candidates.
• Strategic collaborations with major pharmaceutical companies validate its technology.
• Experienced management team with expertise in drug development and commercialization.

What Does NGM Do?

NGM Biopharmaceuticals, Inc., founded in 2007 and headquartered in South San Francisco, California, is a biopharmaceutical company dedicated to the discovery and development of innovative therapeutics. The company focuses on addressing unmet medical needs in liver and metabolic diseases, retinal diseases, and cancer. NGM's lead product candidate, Aldafermin, is an engineered analog of the human hormone fibroblast growth factor 19 (FGF19), currently in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Another key asset, MK-3655, is an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, also in Phase IIb trials for treating type 2 diabetes and NASH. NGM's broader pipeline includes NGM120, an antagonist antibody targeting GFRAL, in Phase I/II trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II trials for geographic atrophy; and NGM707, a dual antagonist monoclonal antibody targeting immunoglobulin-like transcript 2/immunoglobulin-like transcript 4, in Phase I/II trials for advanced solid tumors. Additionally, NGM is developing NGM831 and NGM438 for advanced solid tumors. The company collaborates with Merck Sharp & Dohme Corp. and Merck & Co., Inc., focusing on developing novel medicines for retinal and cardiovascular-metabolic (CVM) diseases, including heart failure. NGM operates with a team of 138 employees, striving to translate innovative science into impactful therapies.

What Products and Services Does NGM Offer?

• Discovers and develops novel therapeutics for liver diseases.
• Focuses on treatments for metabolic diseases like type 2 diabetes and NASH.
• Develops therapies for retinal diseases, including geographic atrophy.
• Engages in research and development of cancer treatments.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Collaborates with pharmaceutical companies for research and development.
• Utilizes engineered analogs and antibodies to target specific disease pathways.

How Does NGM Make Money?

• Develops proprietary drug candidates through internal research and development.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
• Generates revenue through milestone payments and royalties from partnered programs.
• Funds research and development through equity financing and strategic collaborations.

What Industry Does NGM Operate In?

NGM Biopharmaceuticals operates within the highly competitive biotechnology industry, characterized by intense research and development, stringent regulatory requirements, and high capital needs. The company focuses on liver, metabolic, and retinal diseases, and cancer, aligning with significant unmet medical needs and large market opportunities. The NASH market, in particular, is expected to grow substantially in the coming years, driven by the increasing prevalence of obesity and diabetes. Competition includes established pharmaceutical companies and other biotech firms developing novel therapies for these indications.

Who Are NGM's Key Customers?

• Large pharmaceutical companies seeking to expand their pipelines.
• Patients suffering from liver, metabolic, and retinal diseases, and cancer.
• Healthcare providers who prescribe and administer NGM's therapies.
• Research institutions and collaborators involved in clinical trials.

Wall Street analysts project NGM Biopharmaceuticals revenue of about $35.7M for fiscal 2026, with EPS near $-0.43. The estimate reflects 4 contributing analysts.

NGM Biopharmaceuticals's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.08 places it in the distress zone, a signal of elevated financial risk.

Return on equity for NGM Biopharmaceuticals stands at -69.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -84.3%, showing how much profit it generates from its asset base. A current ratio of 7.79 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -112.1%, the inverse of the P/E and a quick read on earnings relative to price.

NGM Biopharmaceuticals (NGM) Valuation Context

Valued at $129M, NGM is classified as a micro-cap stock.

Company Profile

NGM Biopharmaceuticals operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO David J. Woodhouse. NGM has traded publicly since 2019.

NGM Financials

NGM Latest News

NGM Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources